{"organizations": [], "uuid": "80795696f223a0ad21fdeefbee1de068c6eac705", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-corcept-therapeutics-q4-gaap-earni/brief-corcept-therapeutics-q4-gaap-earnings-per-share-0-77-idUSL8N1QC946", "country": "US", "domain_rank": 408, "title": "BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T00:25:00.000+02:00", "replies_count": 0, "uuid": "80795696f223a0ad21fdeefbee1de068c6eac705"}, "author": "", "url": "https://www.reuters.com/article/brief-corcept-therapeutics-q4-gaap-earni/brief-corcept-therapeutics-q4-gaap-earnings-per-share-0-77-idUSL8N1QC946", "ord_in_thread": 0, "title": "BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "corcept therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - Corcept Therapeutics Inc:\n* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL\n* Q4 GAAP EARNINGS PER SHARE $0.77 * Q4 REVENUE ROSE 124 PERCENT TO $53.3 MILLION * REPORTS 2017 REVENUE $159.2 MILLION * SEES FY 2018 REVENUE $275 MILLION TO $300 MILLION * QUARTERLY NON-GAAP NET INCOME PER SHARE $0.19\n* Q4 EARNINGS PER SHARE VIEW $0.18, REVENUE VIEW $53.7 MILLION -- THOMSON REUTERS I/B/E/S\n* CORCEPT THERAPEUTICS - ‍ INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL SHOW NO EVIDENCE OF PROGESTERONE RECEPTOR AFFINITY; NO SERIOUS ADVERSE EVENTS​\n* ‍RELACORILANT TRIAL SHOWS STATISTICALLY SIGNIFICANT, DOSE-DEPENDENT IMPROVEMENTS IN GLUCOSE TOLERANCE , SERUM OSTEOCALCIN​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-23T00:25:00.000+02:00", "crawled": "2018-02-23T00:41:08.010+02:00", "highlightTitle": ""}